Literature DB >> 34285344

Preemptive donor-derived anti-CD19 CAR T-cell infusion showed a promising anti-leukemia effect against relapse in MRD-positive B-ALL after allogeneic hematopoietic stem cell transplantation.

Xiang-Yu Zhao1, Zheng-Li Xu1, Xiao-Dong Mo1, Yu-Hong Chen1, Meng Lv1, Yi-Fei Cheng1, Huan Chen1, Ying-Jun Chang1, Lan-Ping Xu1, Yu Wang1, Xiao-Hui Zhang1, Kai-Yan Liu1, Xiao-Jun Huang2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34285344     DOI： 10.1038/s41375-021-01351-w

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  11 in total

Review 1.  Mechanisms of resistance to CAR T cell therapy.

Authors:  Nirali N Shah; Terry J Fry
Journal:  Nat Rev Clin Oncol       Date:  2019-06       Impact factor: 66.675

2.  Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.

Authors:  James N Kochenderfer; Mark E Dudley; Robert O Carpenter; Sadik H Kassim; Jeremy J Rose; William G Telford; Frances T Hakim; David C Halverson; Daniel H Fowler; Nancy M Hardy; Anthony R Mato; Dennis D Hickstein; Juan C Gea-Banacloche; Steven Z Pavletic; Claude Sportes; Irina Maric; Steven A Feldman; Brenna G Hansen; Jennifer S Wilder; Bazetta Blacklock-Schuver; Bipulendu Jena; Michael R Bishop; Ronald E Gress; Steven A Rosenberg
Journal:  Blood       Date:  2013-09-20       Impact factor: 22.113

3.  Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL.

Authors:  Brent Wood; David Wu; Beryl Crossley; Yunfeng Dai; David Williamson; Charles Gawad; Michael J Borowitz; Meenakshi Devidas; Kelly W Maloney; Eric Larsen; Naomi Winick; Elizabeth Raetz; William L Carroll; Stephen P Hunger; Mignon L Loh; Harlan Robins; Ilan Kirsch
Journal:  Blood       Date:  2017-12-28       Impact factor: 22.113

Review 4.  Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review.

Authors:  Faiz Anwer; Al-Aman Shaukat; Umar Zahid; Muhammad Husnain; Ali McBride; Daniel Persky; Melissa Lim; Nida Hasan; Irbaz Bin Riaz
Journal:  Immunotherapy       Date:  2017-01       Impact factor: 4.196

5.  Salvage chemotherapy followed by granulocyte colony-stimulating factor-primed donor leukocyte infusion with graft-vs.-host disease control for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: prognostic factors and clinical outcomes.

Authors:  Xiao-Dong Mo; Xiao-Hui Zhang; Lan-Ping Xu; Yu Wang; Chen-Hua Yan; Huan Chen; Yu-Hong Chen; Wei Han; Feng-Rong Wang; Jing-Zhi Wang; Kai-Yan Liu; Xiao-Jun Huang
Journal:  Eur J Haematol       Date:  2015-06-25       Impact factor: 2.997

6.  Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.

Authors:  Xiao-Dong Mo; Xiao-Hui Zhang; Lan-Ping Xu; Yu Wang; Chen-Hua Yan; Huan Chen; Yu-Hong Chen; Wei Han; Feng-Rong Wang; Jing-Zhi Wang; Kai-Yan Liu; Xiao-Jun Huang
Journal:  Ann Hematol       Date:  2017-03-11       Impact factor: 3.673

7.  Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation.

Authors:  Chen-Hua Yan; Dai-Hong Liu; Kai-Yan Liu; Lan-Ping Xu; Yan-Rong Liu; Huan Chen; Wei Han; Yu Wang; Ya-Zhen Qin; Xiao-Jun Huang
Journal:  Blood       Date:  2012-02-14       Impact factor: 22.113

8.  Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation.

Authors:  Yuhong Chen; Yifei Cheng; Pan Suo; Chenhua Yan; Yu Wang; Yao Chen; Wei Han; Lanping Xu; Xiaohui Zhang; Kaiyan Liu; Lungji Chang; Lei Xiao; Xiaojun Huang
Journal:  Br J Haematol       Date:  2017-10-26       Impact factor: 6.998

9.  Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.

Authors:  Jennifer N Brudno; Robert P T Somerville; Victoria Shi; Jeremy J Rose; David C Halverson; Daniel H Fowler; Juan C Gea-Banacloche; Steven Z Pavletic; Dennis D Hickstein; Tangying L Lu; Steven A Feldman; Alexander T Iwamoto; Roger Kurlander; Irina Maric; Andre Goy; Brenna G Hansen; Jennifer S Wilder; Bazetta Blacklock-Schuver; Frances T Hakim; Steven A Rosenberg; Ronald E Gress; James N Kochenderfer
Journal:  J Clin Oncol       Date:  2016-01-25       Impact factor: 44.544

10.  Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant.

Authors:  Cheng Zhang; Xiao-Qi Wang; Rong-Li Zhang; Fang Liu; Yi Wang; Zhi-Ling Yan; Yong-Ping Song; Ting Yang; Ping Li; Zhen Wang; Ying-Ying Ma; Lei Gao; Yao Liu; Li Gao; Pei-Yan Kong; Jun Liu; Xu Tan; Jiang F Zhong; Yu-Qing Chen; Ai-Bin Liang; Jin-Hua Ren; Zhen-Yu Li; Jiang Cao; Quan-Li Gao; Jian Zhou; Ying Gao; Ding Zhang; Fang-Yi Fan; Ming-Zhe Han; Robert Peter Gale; Xi Zhang
Journal:  Leukemia       Date:  2020-10-19       Impact factor: 11.528
View more
  2 in total

1.  [Consensus of Chinese experts on chimeric antigen receptor T cell therapy for adult acute B-cell lymphoblastic leukemia (2022)].

Authors: 
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2022-02-14

Review 2.  Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies.

Authors:  Xinyi Xiao; Yazhuo Wang; Zhengbang Zou; Yufei Yang; Xinyu Wang; Xin Xin; Sanfang Tu; Yuhua Li
Journal:  Front Immunol       Date:  2022-08-23       Impact factor: 8.786
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.